The pharmaceutical industry has called for abolishing “off-year” drug price revisions in the run-up to the formulation of the 2024 Basic Policy on Economic and Fiscal Management and Reform (honebuto) later in June. It appears that its lobbying efforts have…
HOME > COMMENTARY
COMMENTARY
- SURVEY/DPP-4 Inhibitors May Decrease Consumption of SUs
December 1, 2008
- COMMENTARY/Thinking about Why Megapharmas Are Closing Research Labs in Japan
November 24, 2008
- COMMENTARY/Marriage of Nos. 1 and 2 Wholesalers Creates Sensation in Market
November 3, 2008
- COMMENTARY/Competition Intensifies for Development of DPP-4 Inhibitors
September 22, 2008
- COMMENTARY/Yamato Searches for a Way to Start Generics Distribution Business
September 22, 2008
- COMMENTARY/Reform of Ethical Drug Distribution Practices
September 1, 2008
- COMMENTARY/Gov't to Cut Social Security Spending by \220 Bil by Promoting Use of Generics
August 25, 2008
- COMMENTARY/Development Race for RNAi Therapeutics Heating Up in Japan
August 4, 2008
- COMMENTARY 4 articles
July 28, 2008
- COMMENTARY/Industry Needs More Creative Thinking: NHI Pricing System Reform
July 21, 2008
- COMMENTARY/Will Fiscal Rehabilitation Policy Be Maintained?
July 7, 2008
- COMMENTARY/Daiichi Sankyo Surprises the World by Announcing Acquisition of Ranbaxy
June 30, 2008
- Pharmaceutical Partnerships in Japan for Regulatory and Commercial Success
June 30, 2008
- COMMENTARY 4 articles
June 9, 2008
- COMMENTARY/Shaking Pharmaceutical Administration System
May 19, 2008
- COMMENTARY/Personnel Strategy -New Graduates or Work-Ready MRs?
April 21, 2008
- COMMENTARY/Industry-Academia Cooperation Essential for Practical Use of iPS Cells
April 21, 2008
- COMMENTARY/Improvement of Drug Distribution Business Practices Goes into Crucial Stretch
April 14, 2008
- COMMENTARY/Mr Kodama Owes His Sweeping Victory to Members' Desire for Change: JPA
March 31, 2008
- COMMENTARY/Most Mainstay Products Avoid Deep Price Cuts in FY2008 NHI Price Revision
March 31, 2008
ページ
The pharmaceutical industry is ever-changing. Recruiters must evolve accordingly and prepare well in advance for future talent needs.This means predicting the changes and trends that will impact the market, industry, and your organization, and how this will affect talent requirements.…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…